The potential of advanced therapies like mRNA to tackle complex diseases with precision is transforming healthcare. mRNA-based treatments can be designed to instruct the body’s own cells to produce therapeutic proteins, enabling innovative approaches for vaccines, rare genetic conditions, and other challenging disorders.
At IDT Australia, we utilise robust aseptic processing and stringent cGMP compliance to deliver fully compliant manufacturing solutions for these emerging technologies. We can help partners progress mRNA therapies from preclinical research through clinical trials and beyond, supporting the path from concept to patient-ready product.
IDT Australia was the first manufacturer in the Southern Hemisphere to produce a COVID-19 mRNA vaccine – achieving this within three months from technical transfer to finished product manufacture. This success was made possible by strong collaborations with leading research partners, including Monash University and The Doherty Institute.
Conducted >17 DoE trials on LNP formulation prior to GMP mRNA manufacture
First GMP COVID-19 vaccine in the Southern HemisphereRead MoreVictoria Makes Australia’s First mRNA Vaccine Candidate
Manufactured and released >17 mRNA vaccine candidates for human clinical trials
Established strong local and global partnerships, including with Sanofi
If you’re looking for quality, turnkey cGMP contract manufacturing services, get in touch with us today to speak with one of our advanced therapy specialists.
Talk To An ExpertIf you’re looking for quality, turnkey cGMP contract manufacturing services, get in touch with us today to speak with one of our advanced therapy specialists.
Talk to an expert